Sudan Laganathan

Sudan Loganathan, PhD is a Managing Director and equity research analyst at Stephens Inc., specializing in biotechnology equities with a focus on oncology, immunology, and rare diseases. He covers key companies such as IDEAYA Biosciences and INOVIO Pharmaceuticals, offering institutional clients in-depth research and hosting industry events; while public track-record metrics like TipRanks rankings or average returns have not been disclosed, he is recognized for his tenure and expertise in the sector. Loganathan began his career as an equity research associate or senior associate at Cantor Fitzgerald, H.C. Wainwright, and RBC Capital Markets, and joined Stephens in May 2023. He holds a B.S. in Biomedical Sciences from Murray State University and a Ph.D. in Neuroscience, Cancer Biology, and Pharmacology from Meharry Medical College and Vanderbilt University Medical Center; his profile indicates professional registration as an analyst but does not detail specific securities licenses.